Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

The findings suggest that "supportive care and management of geriatric vulnerabilities at baseline may improve outcomes and ...

Today the American Cancer Society called out the need for more progress on pancreatic cancer, citing it as the third-leading ...

Gastroenterologist Dr. Rohan Mandaliya of The Center for Comprehensive Pancreatic Care at Mercy goes over the risk factors of ...

Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials ...